This extensive drug table describes the drug and food interactions associated with many oral therapies for cancer.
C.D. is a 71‐year‐old man who was diagnosed with multiple myeloma six weeks ago. At the time of diagnosis, several comorbidities were noted:
"Assessment of Neutropenia-Related Quality of Life in a Clinical Setting," available as a journal article and podcast, explores assessment strategies and recommendations for a questionnaire assessing patients’ neut
In "Neutropenia: State of the Knowledge," a two-part ONS white paper, the authors identify what currently is known and, importantly, not known about the most common dose-limiting toxicity of cancer chemotherapy: chemotherapy-induced neutropenia (CIN).
"Care of Patients With Neutropenia," available as a journal article and podcast, summarizes caring for patients experiencing chemotherapy-induced neutropenia.
Quality of life (QOL) is a broad term that reflects a patient’s overall sense of well-being and satisfaction with living (Ropka & Padilla, 2007).
This slideshow discusses evidence-based interventions for managing neutropenia.
This brief slideshow provides an overview of the causes of neutropenia, as related to chemotherapy and other incidences.
Older patients with cancer remain relatively underrepresented in clinical trials in general, let alone in trials examining exercise and its effects.
The first real research linking exercise to improved quality of life (QOL) and management of fatigue was done by Winningham, MacVicar, and Burke (1986) with a population of patients with breast cancer during a time in medical thinking when the typical recommendation for patients with cancer was increased rest.
"Use of Neurokinin-1 Receptor Antagonists in Patients Receiving Moderately or Highly Emetogenic Chemotherapy," available as a journal article and podcast, discusses the use of neurokinin-1 (NK-1) receptor antagonists in managing chemotherapy-ind
"Chemotherapy-Induced Nausea and Vomiting: Challenges and Opportunities for Improved Patient Outcomes," available as a journal article and podcast, reviews evidence-based guidelines for assessing and managing chemotherapy-induced n
This 18-minute slideshow provides an overview of management principles for chemotherapy-induced nausea and vomiting (CINV) in two parts (1 and 2).
This 13-minute slideshow reviews patient- and treatment-related factors that influence an individual’s risk for chemotherapy-induced nausea and vomiting (CINV).
This three-minute slideshow walks you through the pathophysiology of chemotherapy-induced nausea and vomiting (CINV), including the neurologic pathways involved in CINV.